Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Cut from Cantor Fitzgerald

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price objective cut by Cantor Fitzgerald from $290.00 to $205.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald‘s target price suggests a potential upside of 28.34% from the company’s previous close.

ALNY has been the subject of several other reports. Zacks Research lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Stifel Nicolaus downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price objective on the stock. in a research report on Thursday, October 29th. Bank of America reiterated a “buy” rating and issued a $287.00 target price (down from $460.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 30th. Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating for the company in a report on Friday, October 30th. Finally, Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $292.57.

Read Our Latest Stock Report on ALNY

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $159.73 on Tuesday. The company has a market capitalization of $21.39 billion, a price-to-earnings ratio of 8.29 and a beta of 0.42. Alnylam Pharmaceuticals has a 52 week low of $149.18 and a 52 week high of $479.79. The company has a quick ratio of 2.43, a current ratio of 2.48 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average of $217.12 and a 200 day moving average of $275.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. Alnylam Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.90 earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post 6.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its stake in shares of Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock worth $635,296,000 after acquiring an additional 174,482 shares during the last quarter. Dodge & Cox raised its position in shares of Alnylam Pharmaceuticals by 2.6% in the 3rd quarter. Dodge & Cox now owns 2,006,492 shares of the biopharmaceutical company’s stock valued at $495,082,000 after purchasing an additional 51,099 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Alnylam Pharmaceuticals by 7.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock valued at $219,104,000 after purchasing an additional 50,329 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in Alnylam Pharmaceuticals by 31.5% in the 3rd quarter. First Trust Advisors LP now owns 554,266 shares of the biopharmaceutical company’s stock worth $136,759,000 after purchasing an additional 132,732 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Further Reading

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.